On May 12, RenBio’s President and Chief Scientific Officer, Dr. Rachel Libertore attended the ASGCT 2026 Annual Meeting in Boston, where she presented a poster on DNA-based delivery of broadly neutralizing antibody cocktails as a universal influenza vaccine alternative (Abstract 1101). It was an honor to share the Company’s work on ultra long-lasting DNA medicines using the company’s MYO Technology™ for prevention of infectious disease and treatment of chronic diseases including influenza, psoriasis, neutropenia and others.
Dr. Libertore’s poster (# 1101) can be viewed here.